Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 8/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | CD69 | Q07108 | 1/20 | 0.46 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.41 |
| ▸ | SLC28A3 | Q9HAS3 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16152123 | 0.91 | LGALS8 (0.51) | LGALS8PTPN1CD69SLC28A3THRB | |
| SCHEMBL15250843 | 0.91 | LGALS8 (0.51) | LGALS8PTPN1CD69SLC28A3THRB | |
| SCHEMBL16340826 | 0.91 | LGALS8 (0.51) | LGALS8PTPN1CD69SLC28A3THRB | |
| SCHEMBL13496092 | 0.91 | LGALS8 (0.51) | LGALS8PTPN1CD69SLC28A3THRB | |
| SCHEMBL16342089 | 0.91 | LGALS8 (0.51) | LGALS8PTPN1CD69SLC28A3THRB | |
| SCHEMBL29220914 | 0.90 | LGALS8 (0.71) | LGALS8PTPN1CD69LGALS9LGALS3 | |
| SCHEMBL7539269 | 0.90 | LGALS8 (0.50) | LGALS8PTPN1CD69LGALS9SLC28A3 | |
| SCHEMBL15985656 | 0.90 | LGALS8 (0.50) | LGALS8PTPN1CD69LGALS9SLC28A3 | |
| SCHEMBL7535550 | 0.90 | LGALS8 (0.50) | LGALS8PTPN1CD69LGALS9SLC28A3 | |
| SCHEMBL7539275 | 0.90 | LGALS8 (0.50) | LGALS8PTPN1CD69LGALS9SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160038615-A1 | SACCHARIDE CONJUGATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038615-A1 | SACCHARIDE CONJUGATES | BLM, DCLRE1A, MAN1B1 | LGALS8 132/4885PTPN1 3913/4885CD69 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.